Dyne Therapeutics, Inc
Dyne Therapeutics, Inc. is a biotechnology company operating within the Health Care sector, focused on developing therapeutic solutions, though specific product details are not provided in the available data.
Business. Dyne Therapeutics, Inc. (DYN.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Dyne Therapeutics, Inc. (DYN.O) has entered the scope of financial analysis for the first time, establishing a baseline for future monitoring. As this is the initial assessment for the ticker, there is no prior data available to compute material changes or deltas in performance metrics. The company currently operates with a lean leadership structure, reporting only one officer, and has no coverage from financial analysts or inclusion in major market indices. The most significant recent activity involves a major modification in shareholder holdings detected in late June 2026. Data indicates a substantial shift in the position of investor ID 587 as of March 31, 2026. The records show a discrepancy in reporting, with one signal indicating an increase in shares held by this investor from 3.0 to 918.0, while a subsequent signal suggests a reversal or correction back to 3.0 shares. This volatility in reported ownership highlights the need for careful verification of the final holding status. Despite the fluctuation in this specific investor's reported stake, the overall ownership structure remains broad. Dyne Therapeutics lists 30 top holders, suggesting a distributed shareholder base rather than concentration in a single entity. The value associated with the investor ID 587's position, whether at the higher or lower share count, remains negligible in absolute terms, with values ranging from $0.000054 million to $0.016644 million. The significance of these developments lies in the establishment of a data baseline for a company with minimal public financial infrastructure. With zero analyst coverage and no index membership, Dyne Therapeutics remains a low-profile entity in the market. The resolution of the shareholder reporting anomaly for investor ID 587 will be critical for accurate future tracking of institutional interest and capital allocation within the firm.
Signals & dispatch
Composite-score breakdown
Synthesis
Dyne Therapeutics, Inc. (DYN.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
(a) Capital structure and liquidity: Dyne Therapeutics maintains a conservative balance sheet with total assets of $1.19 billion and total liabilities of $215 million, resulting in a debt-to-equity ratio of 0.15. The company holds $893 million in cash and equivalents, which significantly exceeds its long-term debt of $149 million. This strong cash position supports a low liquidity risk assessment, providing ample runway for operations despite the absence of positive operating cash flow.
(b) Profitability and returns: The company is in a pre-profitability phase, reporting a net loss of $446 million and an operating loss of $468 million. Return on equity stands at -45.9% and return on assets at -37.6%, reflecting the significant capital investment required in early-stage biotechnology development. These negative returns are consistent with the industry norm for clinical-stage biotechs that have not yet achieved commercial revenue scale.
Dyne Therapeutics, Inc. (DYN.O) has entered the scope of financial analysis for the first time, establishing a baseline for future monitoring. As this is the initial assessment for the ticker, there is no prior data available to compute material changes or deltas in performance metrics. The company currently operates with a lean leadership structure, reporting only one officer, and has no coverage from financial analysts or inclusion in major market indices. The most significant recent activity involves a major modification in shareholder holdings detected in late June 2026. Data indicates a substantial shift in the position of investor ID 587 as of March 31, 2026. The records show a discrepancy in reporting, with one signal indicating an increase in shares held by this investor from 3.0 to 918.0, while a subsequent signal suggests a reversal or correction back to 3.0 shares. This volatility in reported ownership highlights the need for careful verification of the final holding status. Despite the fluctuation in this specific investor's reported stake, the overall ownership structure remains broad. Dyne Therapeutics lists 30 top holders, suggesting a distributed shareholder base rather than concentration in a single entity. The value associated with the investor ID 587's position, whether at the higher or lower share count, remains negligible in absolute terms, with values ranging from $0.000054 million to $0.016644 million. The significance of these developments lies in the establishment of a data baseline for a company with minimal public financial infrastructure. With zero analyst coverage and no index membership, Dyne Therapeutics remains a low-profile entity in the market. The resolution of the shareholder reporting anomaly for investor ID 587 will be critical for accurate future tracking of institutional interest and capital allocation within the firm.
- Strong liquidity position with $893 million in cash against $149 million in long-term debt.
- Pre-profitability status with a net loss of $446 million and negative returns on equity and assets.
- Low dilution and liquidity risk, indicating no immediate pressure for equity issuance.
- Absence of specific segment or geographic data suggests a focused, single-segment biotechnology operation.
- No recent corporate events or clinical milestones reported in the available news data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -3,07 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -530,9M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock option (right to buy) → Common StockAcquired 57 463 @ $20,87grant · 2026-06-22
- Director · Stock option (right to buy) → Common StockAcquired 35 152 @ $17,04grant · 2026-06-05
- Director · Stock option (right to buy) → Common StockAcquired 35 152 @ $17,04grant · 2026-06-05
- Director · Stock option (right to buy) → Common StockAcquired 35 152 @ $17,04grant · 2026-06-05
- Director · Stock option (right to buy) → Common StockAcquired 35 152 @ $17,04grant · 2026-06-05
- Director · Stock option (right to buy) → Common StockAcquired 35 152 @ $17,04grant · 2026-06-05
- Director · Stock option (right to buy) → Common StockAcquired 35 152 @ $17,04grant · 2026-06-05
- Director · Stock option (right to buy) → Common StockAcquired 35 152 @ $17,04grant · 2026-06-05
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Return On Equitynet_income / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Assetsnet_income / total_assets
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dyne Therapeutics, Inc. Market data — financials · 2026-07-28
- reconciler_enqueue (reconciler) on DYN.O · 2026-07-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,38 %$1M
- Institutional Investor · as of 2026-03-310,12 %$247M
- Investment Managers · as of 2026-03-310,01 %$36M
- Institutional Investor · as of 2026-03-310,01 %$162M
- Investment Managers · as of 2024-06-300,01 %$261M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$121M
- Investment Managers · as of 2026-03-310,00 %$31M
- Investment Managers · as of 2026-03-310,00 %$64M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$21M
- Investment Managers · as of 2025-12-310,00 %$219M
- Investment Managers · as of 2026-03-310,00 %$22M
- Brokerage Firms · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2024-12-310,00 %$6M
- Institutional Investor · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Funds · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- John CoxPresident, Chief Executive Officer, Director
Insider activity
- Director · Common StockSold 5 388 @ $26,04$140K · 2026-07-27
- Director · Common StockSold 256 072 @ $25,50$6,5M · 2026-07-27
- Director · Common StockSold 49 193 @ $23,17$1,1M · 2026-07-07
- Director · Common StockSold 62 543 @ $23,17$1,4M · 2026-07-07
- Director · Common StockSold 14 844 @ $23,62$351K · 2026-07-07
- Director · Common StockSold 5 000 @ $23,61$118K · 2026-07-07
- Director · Common StockSold 124 379 @ $23,17$2,9M · 2026-07-07
- Director · Common StockSold 11 665 @ $23,62$276K · 2026-07-07
- Director · Common StockSold 29 587 @ $23,62$699K · 2026-07-07
- Director · Common StockSold 100 019 @ $22,79$2,3M · 2026-07-06
- Director · Common StockSold 127 182 @ $22,79$2,9M · 2026-07-06
- Director · Common StockSold 253 039 @ $22,79$5,8M · 2026-07-06
- Director · Common StockSold 40 702 @ $21,14$860K · 2026-06-29
- Director · Common StockSold 102 969 @ $21,14$2,2M · 2026-06-29
- Director · Common StockSold 51 756 @ $21,14$1,1M · 2026-06-29
- Director · Common StockSold 64 411 @ $21,28$1,4M · 2026-06-26
- Director · Common StockSold 81 903 @ $21,28$1,7M · 2026-06-26
- Director · Common StockSold 162 954 @ $21,28$3,5M · 2026-06-26
- Chief Financial Officer · Common StockSold 2 362 @ $20,37$48K · 2026-06-25
- Director · Common StockSold 5 019 @ $21,10$106K · 2026-06-25
- Director · Common StockSold 6 382 @ $21,10$135K · 2026-06-25
- Director · Common StockSold 12 699 @ $21,10$268K · 2026-06-25
- Director · Common StockSold 19 973 @ $21,02$420K · 2026-06-24
- Director · Common StockSold 25 397 @ $21,02$534K · 2026-06-24
- Director · Common StockSold 50 530 @ $21,02$1,1M · 2026-06-24
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cash & equivalents (annual): USD 893.37MUnknown
- Shareholders' equity (annual): USD 972.13MUnknown
- Operating cash flow (annual): USD -403.21MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -3Unknown
- Operating income (annual): USD -468.18MUnknown
- Current assets (annual): USD 1.13BUnknown
- Net income (annual): USD -446Unknown
- EPS (basic) (annual): USD-PER-SHARES -3Unknown
- R&D expense (annual): USD 398.33MUnknown
- Total assets (annual): USD 1.19BUnknown
- Total operating expenses (annual): USD 468.18MUnknown
- Capex (annual): USD 1.92MUnknown
- Total liabilities (annual): USD 214.83MUnknown
- Current liabilities (annual): USD 50.62MUnknown
- Shares outstanding (annual): 164.95MUnknown
- Long-term debt (annual): USD 148.92MUnknown
- Capex (annual): USD 2.38MUnknown
- Total liabilities (annual): USD 61.4MUnknown
- Current liabilities (annual): USD 42.26MUnknown
- Current assets (annual): USD 659.28MUnknown
- R&D expense (annual): USD 281.41MUnknown
- Shareholders' equity (annual): USD 629.84MUnknown
- Cash & equivalents (annual): USD 435.45MUnknown
- Long-term debt (annual): USD 0Unknown